{rfName}
Ot

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Castrillo, JmAuthorBellas, CAuthorRivas, CAuthor

Share

Publications
>
Article

Other cancers in patients with gastric MALT lymphoma

Publicated to:LEUKEMIA & LYMPHOMA. 33 (1-2): 161-168 - 1999-01-01 33(1-2), DOI: 10.3109/10428199909093738

Authors: Montalbàn C; Castrillo J; López-Abente G; Abraira V; Serrano M; Bellas C; Piris M; Carrion R; Cruz M; García-Laraña J; Menarguez J; Rivas C

Affiliations

Cancer Epidemiol. U. Natl. Ctr. E., Carlos III Institute of Health, Madrid, Spain - Author
Department Af Pathology, Univ. de Alcalà de Henares, Madrid, Spain - Author
Department of Hematology and, Univ. de Alcalà de Henares, Madrid, Spain - Author
Department of Internal Medicine, Hospital Ramon y Cajal, Carretera de Colmenar Km 9, Madrid 28034, Spain - Author
Department of Internal Medicine, Univ. de Alcalà de Henares, Madrid, Spain - Author
Department of Internal Medicine, Universidad Autónoma, Madrid, Spain - Author
Department of Oncology, Hospital Virgen de la Salud, Toledo, Spain - Author
Department of Oncology, Universidad Camplutense, Madrid, Spain - Author
Department of Pathology, Fundeción Jimenez Díaz, Universidad Autónoma, Madrid, Spain - Author
Department of Pathology, Hospital Gregorio Marañon, Universidad Camplutense, Madrid, Spain - Author
Department of Pathology, Hospital Virgen de la Salud, Toledo, Spain - Author
Dept. of Clinical Biostatistics Unit, Hospital Ramón y Cajal, Univ. de Alcalà de Henares, Madrid, Spain - Author
See more

Abstract

Patients with Hodgkin's disease and nodal non-Hodgkin's lymphomas seem to have an excess risk for other cancers. A high incidence of other cancers has also been found in some series of patients with gastric MALT lymphomas. In a series of 136 patients with gastric MALT lymphomas the occurrence and features of other cancers have been described. In order to evaluate their occurrence statistically (excluding skin cancers) standard incidence ratios (SRI) have been calculated, using the incidence rates of a Cancer Registry in Spain as a reference. A Cox's multivariate proportional hazard model was fitted in order to evaluate the influence of age, sex, histological grade and treatment with chemotherapy or chemotherapy plus radiotherapy in the development of other non-skin cancers occurring after the diagnosis of MALT lymphoma. Other cancers were detected in 16 of the 136 patients (11.7%); the other cancer was detected prior to MALT gastric lymphoma in 6 patients (4.41%), concomitantly in 4 (2.9%) and after diagnosis of the lymphoma in 6 (4.41%). Other cancers occurred in 14.4% of the male and in 8.3% of the female patients; in 12% of the patients with low grade and in 11% of the patients with high grade lymphomas. Of the 6 cancers that occurred after diagnosis of the gastric lymphoma, 3 did in the 80 patients (3.7%) that had been treated with chemotherapy, 1 in the 3 cases (33%) treated with chemotherapy and radiotherapy and 2 in the 53 patients (3.7%) who had not received chemotherapy or radiotherapy. The most frequent other cancers were lymphoid neoplasms and gastric carcinoma. There was not an excess of other cancers in the whole cohort or in the sex or histological grade strata. There was an excess close to significance (SIR =2.59; 95% CI:0.98-6.88) in the patients under 50 years of age. In the Cox's analysis, age, sex, histological grade and treatment did not influence the occurrence of other cancers after the diagnosis of lymphoma. In conclusion, in patients with gastric MALT lymphoma other cancers also occur. An excess incidence was not demonstrated, although it may exist in patients under 50 years. Of special importance is the occurrence of gastric cancer that appears concomitantly or after gastric lymphoma.

Keywords

AdenocarcinomaAdultAgeAge factorsAgedArticleBiliary tract neoplasmsCancerCancer chemotherapyCancer gradingCancer registryCancer riskCancer statisticsCohort studiesColonic neoplasmsDisease associationFemaleGastric cancerGastric malt lymphomaGenderHistologyHumanHumansIncidenceLaryngeal neoplasmsLymphoma, mucosa-associated lymphoid tissueMajor clinical studyMaleMalt lymphomaMiddle agedMultivariate analysisNeoplasms, multiple primaryNeoplasms, second primaryPriority journalProportional hazards modelsSecond cancersSex factorsStomach carcinomaStomach lymphomaStomach neoplasmsUrinary bladder neoplasms

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal LEUKEMIA & LYMPHOMA due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 1999, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Oncology. Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Hematology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-06-30:

  • WoS: 31
  • Scopus: 34
  • Europe PMC: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-30:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 7 (PlumX).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (RIVAS MANGA, CARMEN).